Merotyle S EDTA 1.6 is a powerful combination injectable antibiotic formulation used for the treatment of severe and multidrug-resistant bacterial infections. This formulation integrates the potent carbapenem antibiotic Meropenem, the beta-lactamase inhibitor Sulbactam Sodium, and Disodium EDTA, a chelating agent that enhances antimicrobial efficacy by disrupting bacterial biofilms and improving antibiotic penetration.
Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis, making it highly effective against both Gram-positive and Gram-negative bacteria, including many resistant strains. Sulbactam Sodium works synergistically by inhibiting beta-lactamase enzymes, which are often produced by bacteria to resist antibiotics. This ensures enhanced activity of Meropenem against resistant pathogens. Disodium EDTA further augments the spectrum of action by breaking down the bacterial outer membrane and reducing the resistance posed by biofilms, especially in hospital-acquired infections.
Merotyle S EDTA 1.6 is particularly effective in managing nosocomial infections, including hospital-acquired pneumonia, complicated urinary tract infections, intra-abdominal infections, septicemia, meningitis, and skin/soft tissue infections caused by resistant organisms like Pseudomonas aeruginosa and Acinetobacter baumannii. Its triple-action formulation makes it a preferred choice in intensive care units and in the treatment of patients with complex or persistent infections.
Administered intravenously, this formulation is reserved for serious infections under medical supervision. Dosage and duration are based on the type and severity of infection, renal function, and patient's clinical status.
The addition of EDTA is a novel strategy aimed at combating rising antimicrobial resistance. By enhancing antibiotic uptake and preventing efflux mechanisms, it improves the effectiveness of the antimicrobial regimen, especially in critical care settings.